PARIS (Reuters) - The French government needs guarantees from drugmaker Sanofi that production of its popular Doliprane ...

Sanofi, which is joining a growing number of drugmakers shedding consumer related businesses, said Opella had been valued at ...

Sanofi confirmed on Monday plans to sell a controlling stake in its over-the-counter unit to a US investment fund, ...

PARIS (Reuters) -French unions have called on workers at Sanofi to strike from Thursday to protest a planned sale of the ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

French pharamceutical giant Sanofi has confirmed plans to sell a controlling stake in its over-the-counter unit to a US ...

Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French ...

Under the proposed deal, the PE firm would take a controlling 50% stake in Sanofi’s Opella unit, with state-owned Bpifrance taking a minority 2% position.

Sanofi is in talks with CD&R to sell a 50% stake in its consumer healthcare unit, Opella. PAI Partners raised its bid by 200 ...

Sanofi said. Bpifrance is expected to participate as a minority shareholder with a c.2% stake. Headquartered in France, Opella employs over 11,000 people, operates in 100 countries with 13 ...

France will take a stake in Sanofi’s Opella through the Public Investment Bank, or BPI, finance minister Antoine Armand said on Sunday, confirming an information from Le Figaro ...

The French government will need guarantees that production of Doliprane will stay in France to allow the sale of the Sanofi's consumer health branch to go ahead, economy minister Antoine Armand ...